Radiology · 2012 · 114 citations · 3 references
PharmacyNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyLabeling RegulationBiologic Product LabelingContrast AgentsLabeling ComplianceMedication Labeling RequirementsPrescription Labeling StandardsContrast Agent SafetyDrug Label DesignDrug Label FormatDrug Labeling StandardsLabelingProduct Labeling UpdatesRadiologic ImagingSafe Labeling
In 2007, the Food and Drug Administration requested that manufacturers of all approved gadolinium-based contrast agents (GBCAs), drugs widely used in magnetic resonance imaging, use nearly identical text in their product labeling to describe the risk of nephrogenic systemic fibrosis (NSF). Accumulating information about NSF risks led to revision of the labeling text for all of these drugs in 2010. The present report summarizes the basis and purpose of this class-labeling approach and describes some of the related challenges, given the evolutionary nature of the NSF risk evidence. The class-labeling approach for presentation of product risk is designed to decrease the occurrence of NSF and to enhance the safe use of GBCAs in radiologic practice.
3
Response to the FDA's May 23, 2007, Nephrogenic Systemic Fibrosis Update
Emanuel Kanal, Dale R. Broome, Diego R. Martín et al. · Radiology · 2007 · 91 citations
Medicine, Nephrology, Pathology +10